Core Viewpoint - Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares for gross proceeds of up to $600 million, with the meeting scheduled for September 26, 2025 [1][2]. Group 1: Offering Details - The entire offering is expected to be subscribed by existing holders of MVS and is anticipated to close on or about September 26, 2025, pending shareholder approval [2]. - Proceeds from the offering will be used for general working capital purposes [2]. - All securities issued will be subject to a statutory hold period of four months plus a day from issuance in accordance with Canadian securities laws [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [5]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [5]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will drop to 3% [5].

Core Insights - Quantum BioPharma Ltd. has received a clinical study report (CSR) confirming the safety and tolerability of its compound Lucid-MS in a Phase 1 trial involving healthy participants [1][3][4] - Lucid-MS is a first-in-class neuroprotective compound aimed at treating multiple sclerosis (MS) and has demonstrated the ability to prevent demyelination in preclinical models [2][5] - The company is preparing to advance the clinical development of Lucid-MS towards efficacy trials in MS patients following the positive CSR results [4][5] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, in its portfolio [5] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [5] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial properties [5]

Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities in a market manipulation lawsuit, alleging damages exceeding $700 million USD due to "spoofing" techniques that artificially depressed its stock price [1][2][4]. Legal Proceedings - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants engaged in market manipulation that violated the Securities Exchange Act of 1934 [2]. - Quantum BioPharma's amended complaint was filed on May 31, 2025, in response to the defendants' memorandum of law filed on June 16, 2025 [2][3]. Financial Implications - Quantum BioPharma is seeking over $700 million USD in damages due to the alleged market manipulation [2]. - The company's stock was trading over $460 USD per share in January 2020, with a market capitalization approaching $1 billion USD [5]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted an extensive investigation and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Background - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement that could yield up to $250 million [10].

Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities, alleging market manipulation that harmed the company's stock price and seeking over $700 million in damages [1][2]. Legal Proceedings - The company filed an amended complaint on May 31, 2025, alleging that the defendants engaged in market manipulation schemes violating the Securities Exchange Act of 1934 [2]. - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants used "spoofing" techniques to manipulate Quantum BioPharma's share price [2][4]. - The company has made all relevant legal documents available on its website for public access [3]. Financial Impact - Quantum BioPharma's stock was trading over $460 per share in January 2020, with a market capitalization nearing $1 billion [5]. - The company is seeking damages exceeding $700 million due to the alleged manipulation, which it claims has significantly harmed both the company and its investors [2][4]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted extensive investigations and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [10]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., with a royalty agreement that could yield significant future revenue [10].

Core Insights - Quantum BioPharma Ltd. has submitted its patented drug candidate Lucid-21-302 (Lucid-MS) for the Innovative Licensing and Access Pathway (ILAP) Passport program in the UK, aiming to provide a new treatment for multiple sclerosis (MS) [1][3] Group 1: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [4] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models [4] - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty will drop to 3% [4] Group 2: ILAP Passport Program - The ILAP Passport is designed to expedite the development and delivery of groundbreaking medicines by fostering collaboration among medicine developers, regulatory bodies, and the NHS [2] - The program aims to streamline the process of developing, reviewing, approving, and delivering new treatments to patients, ensuring timely access to medical innovations [2] Group 3: Statements from Company Executives - Dr. Andrzej Chruscinski expressed excitement about the ILAP Passport submission, highlighting its potential to accelerate clinical development and patient access to Lucid-21-302 [3] - Dr. Lakshmi P. Kotra emphasized the company's commitment to bringing innovative drugs to patients quickly and the importance of global regulatory strategies [4]

Core Viewpoint - Quantum BioPharma Ltd. is completing a non-brokered private placement of class A multiple voting shares at a price of $50 per share, aiming for gross proceeds of up to $600 million, expected to be fully subscribed by existing holders of MVS [1][3]. Group 1: Offering Details - The Offering consists of class A multiple voting shares priced at $50 each, with total gross proceeds anticipated to reach $600 million [1]. - All securities issued in the Offering are subject to a statutory hold period of four months plus a day from issuance, in accordance with Canadian securities laws [2]. - The proceeds from the Offering will be utilized for general working capital purposes [2]. Group 2: Insider Participation - The Offering is expected to be fully subscribed by Xorax Family Trust and Fortius Research and Trading Corp., both of which have insider connections to the Company [3]. - The participation of these insiders is classified as a "related-party transaction" under Multilateral Instrument 61-101, with exemptions from formal valuation and minority shareholder approval requirements being relied upon [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [6]. - The Company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% on sales until reaching $250 million, after which the royalty rate will decrease to 3% [6].

Core Viewpoint - Quantum BioPharma Ltd. announces that Unbuzzd Wellness Inc. is raising up to US$5 million through a Regulation D 506(c) offering to support its expansion plans for the unbuzzd™ beverage, which accelerates alcohol metabolism and reduces hangover symptoms [1][2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [3] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments on unbuzzd™ sales until reaching $250 million, after which the royalty rate drops to 3% [3] Product Details - Unbuzzd™ is a scientifically-backed beverage designed to help alcohol consumers process alcohol faster, restore mental clarity, and alleviate hangover symptoms [5][6] - Clinical trials show that unbuzzd accelerates alcohol metabolism, reducing blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [6][13] - Participants reported significant improvements in alertness and reductions in hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [13] Leadership and Strategy - John Duffy, CEO of Unbuzzd, emphasizes the commitment to providing a scientifically backed product to alcohol consumers and the importance of the capital raise for expansion [2] - Gerry David, Board Co-Chair, highlights that the capital raise will support company growth and position unbuzzd for a potential initial public offering [3]

Core Insights - Quantum BioPharma Ltd. is making significant advancements in its clinical pipeline, particularly with its FSD202 program targeting nociplastic pain in patients with Idiopathic Mast Cell Activation Syndrome (MCAS) and its Lucid-MS program for progressive Multiple Sclerosis [2][3] Clinical Development Milestones - The FSD202 program has received HREC approval for a Phase 2 clinical trial, enrolling 60 patients to assess pain reduction over 28 days [2] - The Lucid-MS program is expected to file an IND application with the U.S. FDA in Q4 2025, which would allow progression to Phase 2 trials [3] Strategic Business Developments - The subsidiary Celly Nutrition has rebranded to Unbuzzd Wellness Inc. and is preparing for a potential IPO to enhance capital for marketing its alcohol metabolism product [4] - Quantum BioPharma holds a 20.11% stake in Unbuzzd Wellness, positioning it to benefit from the subsidiary's growth [4] Financial Performance - For Q1 2025, Quantum BioPharma reported no revenues, with general and administrative expenses down 31% to $1.32 million, while R&D expenses rose to $1.65 million [6][7] - The company maintained cash and cash equivalents of $3.5 million as of March 31, 2025, ensuring liquidity through Q1 2027 [7] Pipeline Overview - The company's pipeline includes Lucid-MS for progressive Multiple Sclerosis, FSD202 for MCAS and inflammatory diseases, and unbuzzd™ for alcohol metabolism [8] Investment Strategy - Quantum BioPharma has diversified its treasury holdings towards Bitcoin, with total investments reaching $5 million [5] - The company plans to issue special dividends linked to potential litigation proceeds exceeding $700 million related to alleged stock manipulation [5]

Core Viewpoint - Quantum BioPharma Ltd. intends to declare a special dividend consisting of Contingent Value Rights (CVRs) to holders of its Class B Subordinate Voting Shares, reflecting the company's commitment to its shareholders [1][3]. Group 1: Special Dividend and CVRs - Each CVR will entitle holders to receive a pro rata portion of a minimum of 10% and a maximum of 50% of the net proceeds from the company's legal action against certain banks, seeking damages exceeding USD 700 million for alleged stock price manipulation [2][8]. - The exact payout percentage for the CVRs will be approved by the Board at a later date [2][3]. - The record date for the proposed special dividend has not yet been established, and further updates will be provided [3]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [4]. - The company’s lead compound, Lucid-MS, aims to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [4][8]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach USD 250 million, after which the royalty will drop to 3% [4]. Group 3: Legal and Regulatory Considerations - The issuance of the CVRs is subject to necessary approvals, regulatory requirements, and finalization of tax, legal, and operational matters [3][8]. - There is no assurance that any proceeds from the litigation will be received or that the CVRs will result in any payment to holders [3][7].

Core Viewpoint - Quantum BioPharma Ltd. has purchased an additional USD $5,000,000 worth of Bitcoin and other cryptocurrencies as part of its strategic efforts to enhance shareholder returns and hedge against the dollar [1][2]. Group 1: Cryptocurrency Investment - The total amount of Bitcoin and other cryptocurrencies held by the company now stands at USD $5,000,000 [1]. - The company believes in the potential of cryptocurrencies to provide returns on investment for shareholders [2]. - Quantum BioPharma is set up to receive financing and conduct transactions in cryptocurrencies [2]. Group 2: Compliance and Custodianship - All cryptocurrency holdings are managed by a fully compliant custodian, ensuring adherence to financial and audit regulations [3]. - The company will continue to monitor market conditions and may adjust its cryptocurrency holdings as deemed appropriate [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [4]. - The company retains a 20.11% ownership stake in Celly Nutrition Corp., which includes a royalty agreement of 7% on sales from its product unbuzzd™ until total payments reach USD $250 million [4]. - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4].